Nasdaq ikna.

Ikena Oncology Inc (NASDAQ: IKNA) nominated a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, as its first development candidate in the RAS pathway. The ...Webull offers Ikena Oncology (IKNA) historical stock prices, in-depth market analysis, NASDAQ: IKNA real-time stock quote data, in-depth charts.Oct 26, 2022 · BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. Media Contact Emily Pan [email protected] +1 (646 ...

First Quarter 2022 Financial results. Ikena had $212.4 million in cash, cash equivalents, marketable securities as of March 31, 2022, as compared to $232.2 million as of December 31, 2021. Ikena ...

Ikena Oncology, Inc. (NASDAQ:IKNA) fell 11.6% to close at $28.30. Ikena Oncology surged 100% on Friday after the company priced its IPO at $16 per share. Credit Suisse Group AG ...BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...

Ikena Oncology Stock Earnings. The value each IKNA share was expected to gain vs. the value that each IKNA share actually gained. Ikena Oncology ( IKNA) reported Q3 2023 earnings per share (EPS) of -$0.40, beating estimates of -$0.43 by 7.29%. In the same quarter last year, Ikena Oncology 's earnings per share (EPS) was -$0.48.BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology, Inc.BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company forging new territory in patient-directed cancer treatment, and the Vall d’Hebron ...Analyst Forecast According to 4 analysts, the average rating for IKNA stock is "Strong Buy." The 12-month stock price forecast is $14.25, which is an increase of …

The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.

(NASDAQ: IKNA) Ikena Oncology currently has 48,258,111 outstanding shares. With Ikena Oncology stock trading at $1.40 per share, the total value of Ikena Oncology stock (market capitalization) is $67.56M.Ikena Oncology. stock was originally listed at a price of $28.30 in Mar 29, 2021.

List with Nasdaq; Nasdaq Private Market; Nasdaq Fund Secondaries; Investor Relations Intelligence ; Nasdaq Direct Listings; Optimize Governance Practices. Board Portal …Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology, Inc.BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...Tesla, Inc. (NASDAQ:TSLA) rose 4.4% to close at $691.05 as the company reported that it has delivered 184,800 vehicles in the first quarter, handily exceeding the 168,000 number analysts expected.Find the latest Institutional Holdings data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.Shares of Chembio Diagnostics, Inc. (NASDAQ:CEMI) got a boost, shooting 57% to $5.53 after the company announced the commercial launch of a test to differentiate between COVID-19 and the Flu.

KludeIn I Acquisition Corp. Class A Common Stock (INKA) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.BOSTON--(BUSINESS WIRE)--May 13, 2021-- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced financial results for the quarter ended March 31, 2021.Mar 17, 2022 · BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ... BOSTON--(BUSINESS WIRE)--May 13, 2021-- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced financial results for the quarter ended March 31, 2021.The stock of Ikena Oncology Inc (NASDAQ: IKNA) has increased by 20.81 when compared to last closing price of 1.49.Despite this, the company has seen a gain of 23.29% in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to ...... (IKNA). Nov. 9, 2023 at 2:09 p.m. ET on TipRanks.com. Buy Recommendation for ... Real-time last sale data for U.S. stock quotes reflect trades reported through ...BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Ikena Oncology (NASDAQ: IKNA) is a clinical-stage, targeted oncology company that discovers and develops biomarker-driven therapies for cancer patients who need life-saving treatment by ...IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ...

BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ...Home IKNA • NASDAQ. Ikena Oncology Inc. Follow. Share. $3.61. Oct 19, 12:03:05 PM GMT-4 · USD · NASDAQ · Disclaimer. search Compare to. Lexicon Pharmaceuticals Inc.BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...IKNA. Ikena Oncology, Inc. 1.6300 +0.0300 +1.87%: TRENDING. 1. ... Both the S&P 500 and the NASDAQ indexes are back within close reach of the peak yearly values hit at the end of July, after their ...BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today ...... (NASDAQ: NTLA), and Korro Bio. Jean-François also serves on the boards of Ikena Oncology (NASDAQ: IKNA) and Scorpion Therapeutics. His prior investments ...

IKNANASDAQ See on Supercharts Overview News Ideas Financials Technicals Forecast IKNA chart Today 0.00% 5 days 24.36% 1 month −49.26% 6 months −71.40% Year to date −43.00% 1 year −19.34% 5 …

ABOUT THIS EVENT Ikena Oncology, Inc (Nasdaq: IKNA) rings the Nasdaq Closing Bell remotely from across the country. Mark Manfredi, Ph.D., President & CEO, rings the Closing Bell alongside the ...

7 août 2023 ... (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics ...Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in...Mar 7, 2023 · Follow. BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ... Ikena Oncology, Inc. (IKNA) NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.6700 +0.0900 (+5.70%) As of 10:38AM EST. Market open. 1d. IKNA. Ikena Oncology, Inc. 1.6300 +0.0300 +1.87%: TRENDING. 1. ... Both the S&P 500 and the NASDAQ indexes are back within close reach of the peak yearly values hit at the end of July, after their ...Home IKNA • NASDAQ. Ikena Oncology Inc. Follow. Share. $3.61. Oct 19, 12:03:05 PM GMT-4 · USD · NASDAQ · Disclaimer. search Compare to. Lexicon Pharmaceuticals Inc.Osiris Therapeutics (OTCMKTS:OSIR – Get Free Report) and Ikena Oncology (NASDAQ:IKNA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations. Earnings and Valuation This table compares ...Find the latest Ikena Oncology Inc (IKNA) discussion and analysis from iHub's community of investors ... NASDAQ · Add Alert · Follow. 1. 1.71. 0.00 (0.00%). Quote ...Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology, Inc.Ikena Oncology, Inc. (NASDAQ:IKNA) announced its earnings results on Wednesday, November, 10th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.02. The business earned $3.75 million during the quarter, compared to analysts' expectations of $2.92 million.BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, ... The Invesco QQQ Trust offers a way to play tech strength by matching the Nasdaq 100 index.BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

15 mai 2023 ... (NASDAQ: IKNA) (“Ikena” or the “Company”) is a targeted oncology company, focused on developing differentiated therapies for patients in ...BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, has been nominated as the company’s first development ...As of September 30, 2021, the Company had cash and cash equivalents totaling $245.9 million, which will fund operations through 2023. Net cash used in operations was $18.0 million for the third ...Atreca, Inc. (NASDAQ:BCEL) announced initial data from the dose escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types, showing the investigational asset ...Instagram:https://instagram. ship ediblebest medical insurance in oklahomabest stocks for swing tradelex real estate Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ... is the uaw strike still going onbest options alerts Nov 7, 2022 · Third Quarter 2022 Financial Results. As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient to meet its ... The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st... psec nasdaq BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...May 15, 2023 · Financial Results for the Quarter Ended March 31, 2023. As of March 31, 2023, Ikena had $137.8 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ... Near Intelligence's stock rallies 43% after Benchmark starts coverage with speculative buy rating. Near Intelligence Inc.'s stock NIR, +51.45% rallied 43% Friday, after Benchmark initiated coverage of the stock with a speculative buy rating with analyst Mark Zgutowicz arguing it's undervalued.